Efficacy and Safety of Mirikizumab (LY3074828) in the Treatment of Moderate-To-Severe Plaque Psoriasis: Results From a Randomised Phase 2 Study

British Journal of Dermatology - United Kingdom

doi 10.1111/bjd.17628